Stellungnahme der DGVS zum IQWiG-Bericht Nr. 641 Bezlotoxumab (Clostridium-difficile-Infektion) – Nutzenbewertung gemäß §35a SGB V

doi:10.1055/a-0671-6834

Zeitschrift für Gastroenterologie, Table of Contents

Z Gastroenterol 2018; 56(09): 1173-1175
DOI: 10.1055/a-0671-6834

Mitteilungen der DGVS

Stellungnahme der DGVS zum IQWiG-Bericht Nr. 641 Bezlotoxumab (Clostridium-difficile-Infektion) – Nutzenbewertung gemäß §35a SGB V

Abstract

Full Text

References

Literatur
1 Lawson PA, Citron DM, Tyrrell KL. et al. Reclassification of Clostridium difficile as Clostridioides difficile (Hall and O'Toole 1935) Prévot 1938. Anaerobe 2016; 40: 95-99 . doi:10.1016/j.anaerobe.2016.06.008. Epub 2016 Jun 28
2 Hagel S, Epple HJ, Feurle GE. et al. S2k-Leitlinie Gastrointestinale Infektionen und Morbus Whipple. Z Gastroenterol 2015; 53: 418-459
3 Nationales Referenzzentrum für Surveillance von nosokomialen Infektionen (NRZ). Deutsche nationale Punkt-Prävalenzerhebung zu nosokomialen Infektionen und Antibiotika-Anwendung 2016. Abschlussbericht 2017; 12. März 2018. http://www.nrz-hygiene.de/nrz/praevalenzerhebung/ letzter Aufruf: 16.07.2018
4 Ogielska M, Lanotte P, Le BrunC. et al. Emergence of community-acquired Clostridium difficile infection: the experience of a French hospital and review of the literature. Int J Infect Dis 2015; 37: 36-41 . doi:10.1016/j.ijid.2015.06.007. Epub 2015 Jun 17
5 Kotila SM, Mentula S, Ollgren J. et al. Community- and Healthcare-Associated Clostridium difficile Infections, Finland, 2008 – 2013 (1). Emerg Infect Dis 2016; 22: 1747-1753 . doi:10.3201/eid2210.151492
6 Buendgens L, Bruensing J. et al. Administration of proton pump inhibitors in critically ill medical patients is associated with increased risk of developing Clostridium difficile-associated diarrhea. J Crit Care 2014; 29: 696.e11-5 . doi:10.1016/j.jcrc.2014.03.002. Epub 2014 Mar 7
7 GESUNDHEITSBERICHTERSTATTUNG DES BUNDES – GEMEINSAM GETRAGEN VON RKI UND DESTATIS, Abfrage Sterbefälle A04.7 (Enterokolitis durch Clostridium difficile, 16.07.2018).
8 He M, Miyajima F, Roberts P. et al. Emergence and global spread of epidemic healthcare-associated Clostridium difficile. Nat Genet 2013; 45: 109-113
9 Martin J. The contribution of strains and hosts to outcomes in Clostridium difficile infection. Infectious disease clinics of North America 2015; 29: 51-61
10 Jansen A, Kleinkauf N, Weiss B. et al. Emergence of clostridium difficile ribotype 027 in Germany: epidemiological and clinical characteristics. Z Gastroenterol 2010; 48: 1120-1125 . doi: 10.1055/s-0029-1245269
11 Gerding DN, Muto CA, Owens Jr RC . Treatment of Clostridium difficile infection. Clin Infect Dis 2008; 46 (Suppl. 01) S32-S42
12 Lübbert C, Zimmermann L, Borchert J. et al. Epidemiology and Recurrence Rates of Clostridium difficile Infections in Germany: A Secondary Data Analysis. Infect Dis Ther 2016; 5: 545-554
13 Hagel S, Fischer A, Ehlermann P. et al. Fecal Microbiota Transplant in Patients With Recurrent Clostridium Difficile Infection. Dtsch Arztebl Int 2016; 113 (35 – 36) 583-589
14 Leung DY, Kelly CP, Boguniewicz M. et al. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr 1991; 118 (04) 633-637
15 Grube RF, Heinlein W, Scheffer H. et al. Economic burden of Clostridium difficile enterocolitis in German hospitals based on routine DRG data. Z Gastroenterol 2015; 53: 391-397 . doi:10.1055/s-0034-1398803. Epub 2015 May 12
16 Heimann SM, Vehreschild JJ, Cornely OA. et al. Economic burden of Clostridium difficile associated diarrhoea: a cost-of-illness study from a German tertiary care hospital. Infection 2015; 43: 707-714 . doi:10.1007/s15010-015-0810-x. Epub 2015 Jun 30
17 Kuijper EJ, Coignard B, Tüll P. ESCMID Study Group for Clostridium difficile; EU Member States; European Centre for Disease Prevention and Control. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 2006; 12 (06) 2-18 . doi:10.1111/j.1469-0691.2006.01580.x
18 Wilcox MH, Gerding DN, Poxton IR. et al. Bezlotoxumab for Prevention of Recurrent Clostridium difficile. Infection. N Engl J Med 2017; 376: 305-317
19 Gerding DN, Kelly CP, Rahav G. et al. Bezlotoxumab for prevention of recurrent C. difficile infection in patients at increased risk for recurrence. Clin Infect Dis 2018;